FIBRINOGEN CONCENTRATES MARKET ANALYSIS
Several launches and approvals of new fibrinogen concentrates are expected to boost growth of the fibrinogen concentrates market over the forecast period. For instance, in March 2017, LFB Biopharmaceuticals launched FibCLOT, a human fibrinogen concentrate. FibCLOT is used for the patients with congenital hypo-fibrinogenaemia or afibrinogenaemia.
Europe is also witnessing lucrative growth in the fibrinogen concentrates market owing to launches and approvals of new fibrinogen concentrates in the region. For instance, in June 2017, Octapharma AG received approval from the U.S Food and Drug Administration (FDA) for Fibryna, a human fibrinogen concentrate, developed for the treatment of acute bleeding incidences in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Furthermore, in November 2019, Octapharma AG received the European approval for label extension for fibryga for the treatment of acquired fibrinogen deficiency (AFD) in 15 European countries. The approval extends the market authorisation for fibryga for bleeding management in operative settings.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
